The American Society for Radiation Oncology issued a clinical guideline for the use of whole breast radiation therapy for breast cancer that expands the population of patients recommended to receive accelerated treatment known as hypofractionated therapy.
A newly-published study shows many remain at risk for later complications from chemotherapy or other treatments. The study in the Journal of the National Comprehensive Cancer Network confirms testicular cancer survivors are more likely to develop high blood pressure, high cholesterol, and obesity, which can significantly increase their risk of heart disease.
Cancer immunotherapy, and in particular immune checkpoint blockade, has transformed oncology with the potential for durable responses even in patients with metastatic disease. To date, regulatory approvals and clinical trials have focused on the study of these agents in relatively more common tumor types, such as melanoma, non-small cell lung cancer, bladder cancer, and kidney cancer, amongst others.
Urgent action must be taken to address the dramatic rise of cancer drug prices and to better align prices with value, the President's Cancer Panel urged in a recent report.
The American Association for Cancer Research has launched a collaborative initiative that will perform genomic sequencing of both tumor and normal tissue from 2,020 consented African-American cancer patients, and aggregate it with clinical data from the patients.
Aurora Health Care and University of Texas Health Sciences at Houston have joined the Strata Precision Oncology Network.
Paul Engstrom, the Samuel M.V. Hamilton Chair in Cancer Prevention and special adviser to the president at Fox Chase Cancer Center, will receive the Prevent Cancer Foundation's Laurels Award for Lifetime Achievement in Cancer Prevention.
Margaret Bellerjeau, of the Fox Chase–Temple University Hospital Bone Marrow Transplant Program, received the 2018 Nursing Special Interest Group Lifetime Achievement Award from the American Society for Blood and Marrow Transplantation.
FDA approves new treatment for a certain type of prostate cancer using novel clinical trial endpoint
FDA approved Erleada (apalutamide) for the treatment of patients with prostate cancer that has not spread, but that continues to grow despite treatment with hormone therapy. This is the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer.
